Stellantis cancels Ram 1500 electric pickup citing weak demand
On Thursday, Leerink Partners adjusted their financial outlook for Owens & Minor (NYSE:OMI), reducing the price target from $13.50 to $10.00, while maintaining a Market Perform rating on the healthcare logistics company’s stock. The revision follows Leerink’s update of their fiscal year 2025 earnings before interest, taxes, depreciation, and amortization (EBITDA) estimate, which decreased from $739.3 million to $680.2 million.
The adjustment in EBITDA expectations is attributed solely to the exclusion of Rotech from the second quarter estimates. Additionally, Leerink has revised its fiscal year 2025 earnings per share (EPS) forecast for Owens & Minor from $1.58 to $1.20. The firm clarified that the new estimates account for a mismatch in timing related to a partial second quarter of new interest expenses without an assumed EBITDA contribution.
Leerink’s decision to lower the price target to $10.00 reflects not only the updated estimates but also a shift in group sentiment towards Owens & Minor. Despite the reduction, the price target is still based on approximately 6 times the calendar year 2025 enterprise value/EBITDA estimate provided by Leerink.
The changes in financial projections and price target are a direct response to the current financial data and market conditions impacting Owens & Minor. Leerink’s analysis indicates a more cautious outlook on the company’s future earnings potential, factoring in both internal adjustments and broader market sentiment.
In other recent news, Owens & Minor, Inc. released preliminary financial results for the fourth quarter and full year ending December 31, 2024, which fell short of market expectations. The company reported a net loss ranging from $311 million to $288 million for the fourth quarter, with an adjusted EBITDA of $135 to $140 million, below the consensus estimate of $155.5 million. Revenue for the quarter is projected to be between $2.67 billion and $2.70 billion, missing the consensus estimate of $2.72 billion. Additionally, Owens & Minor anticipates a non-cash goodwill impairment charge of approximately $310 million in its Apria division due to a decline in stock price and rising interest rates. For the full year, the company expects revenue to range from $10.67 billion to $10.70 billion, with a net loss between $378 million and $355 million. Analysts have expressed concerns, with Michael Cherny from Leerink Partners highlighting potential questions about underlying margins and Daniel Grosslight from Citi attributing lower-than-expected results to the Patient Direct business. Despite these challenges, CEO Edward A. Pesicka noted the growth of the Patient Direct segment and a reduction in total debt by over $240 million. The company plans to host an investor conference call on February 28, 2025, to discuss these results in detail.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.